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Background: Magnesium supplementation has previously shown reductions in blood pressure of up to 12 mmHg.
A positive relationship between magnesium supplementation and performance gains in resistance exercise has also
been seen. However, no previous studies have investigated loading strategies to optimise response. The aim of this
study was to assess the effect of oral magnesium supplementation on resistance exercise and vascular response
after intense exercise for an acute and chronic loading strategy on a 2-day repeat protocol.
Methods: The study was a randomised, double-blind, cross-over design, placebo controlled 2 day repeat measure
protocol (n = 13). Intense exercise (40 km time trial) was followed by bench press at 80% 1RM to exhaustion, with
blood pressure and total peripheral resistance (TPR) recorded. 300 mg/d elemental magnesium was supplemented
for either a 1 (A) or 4 (Chr) week loading strategy. Food diaries were recorded.
Results: Dietary magnesium intake was above the Reference Nutrient Intake (RNI) for all groups. Bench press
showed a significant increase of 17.7% (p = 0.031) for A on day 1. On day 2 A showed no decrease in performance
whilst Chr showed a 32.1% decrease. On day 2 post-exercise systolic blood pressure (SBP) was significantly lower in
both A (p = 0.0.47) and Chr (p = 0.016) groups. Diastolic blood pressure (DBP) showed significant decreases on day
2 solely for A (p = 0.047) with no changes in the Chr. TPR reduced for A on days 1 and 2 (p = 0.031) with Chr
showing an increase on day 1 (p = 0.008) and no change on day 2.
Conclusion: There was no cumulative effect of Chr supplementation compared to A. A group showed improvement
for bench press concurring with previous research which was not seen in Chr. On day 2 A showed a small
non-significant increase but not a decrement as expected with Chr showing a decrease. DBP showed reductions
in both Chr and A loading, agreeing with previous literature. This is suggestive of a different mechanism for BP
reduction than for muscular strength. TPR showed greater reductions with A than Chr, which would not be
expected as both interventions had reductions in BP, which is associated with TPR.
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Table 1 Subject characteristics; including group sample
size (n), age, height, weight, VO2max, HRmax
Chronic Acute
N 7 6
Age (years) 40.8 ± 4.4 35.8 ± 6.2
Height (cm) 176.2 ± 11 174.6 ± 12
Weight (kg) 73.2 ± 13.2 72.1 ± 13
VO2max (ml/kg) 51.8 ± 9.1 53 ± 4.8
HRmax (bpm) 176.4 ± 3.8 180.8 ± 7.7
Values are mean ± SD.
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Magnesium (Mg2+) elicits significant enzymatic cellu-
lar involvement and physical regulation such as energy
metabolism/production through formation of the Mg-
ATP complex [1] and physiological regulation and control
of neuromuscular cardiac activity, muscular contraction,
vascular tone and blood pressure [2,3]. Its effect on mus-
cular contraction and vascular tone have been shown
to reduce blood pressure and subsequently vascular
resistance [4].
Nutritional supplementation is a well-established method
for enhancing performance in conjunction to training.
Micronutrient intake has been highlighted to have gained
greater prominence with athletes in relation to the import-
ance of an adequate nutritional status [5], However, previ-
ous research highlights nutritional inadequacies and thus
an impaired nutritional status (i.e. marginal nutrient defi-
ciency) from both an athletic [5] and general population
perspective [6]. This identifies physical activity as increas-
ing the rate at which micronutrients are utilised, promot-
ing excessive micronutrient loss via increased catabolism
and excretion (sweat and urine). Magnesium is a mineral
required at rest and during exercise [7]. This increase in
Mg2+ turnover during exercise may lead to a state of in-
sufficiency acting as a contributory factor towards an in-
crease in blood pressure and a state of hypertension [8].
This, together with a decline in dietary intake below the
RNI may have a negative impact on both performance
and blood pressure.
Magnesium supplementation in relation to exercise has
differed considerably in research opinion as to the dose
and type of Mg2+ salt administered. It is influenced by the
specific anion attachment with Mg2+, thus influencing
supplemental solubility, elemental Mg2+ bioavailability
and supplemental effectiveness [9]. Research has illustrated
organic forms of Mg2+ supplementation i.e. Aspartate, cit-
rate, lactate, pidolate, fumurate, acetate, ascorbate and glu-
conate to exemplify a greater solubility and bioavailability
in comparison to inorganic forms i.e. oxide, sulphate,
chloride and carbonate [10] When considered relative to
the quantity needed to be ingested to release 300 mg of
elemental Mg2+ along with the fact that certain magne-
siums are unavailable in the UK, magnesium citrate was
considered to be the best option for this protocol.
Research to date consists of both positive [11-13] and
negative [14,15] findings. The research appears to agree
that Mg2+ supplementation has no effect on physical per-
formance when serum concentrations are within the
normal range (serum Mg2+ 0.8-1.2 mmol·L−1) [12,16].
However, manipulating intakes of Mg2+ by diet or supple-
mentation has been shown to have performance [11,17]
and blood pressure enhancements [13,18]. Limitations to
many of these studies is the lack of information regard-
ing either serum magnesium or dietary intake [19]. Thegeneral consensus appears to be that Mg2+ supplementa-
tion has a greater effect when habitual dietary intake or
serum levels are low.
Further, to the best of the authors’ knowledge research
to date lacks analysis of Mg2+ from an acute (A) and
chronic (Chr) viewpoint within the same study. Therefore,
the aim of the current study was to assess the effect of oral
Mg2+ supplementation on strength performance and vas-
cular responses from both an A and Chr loading strategy
as to establish potential differences in supplemental dur-
ation and influences of dietary status and supplemental
dose on performance and vascular responses.
Methods
Subjects
A total of 13 subjects (males (m) = 7 females (f ) = 6)
were recruited from recreational running, cycling and
triathlete clubs. Six subjects were allocated randomly to
the acute intervention group (m = 3, f = 3) and 7 to the
chronic intervention group (m = 4, f = 3). Subjects were
recruited in accordance to meeting the inclusion/exclusion
criteria, (Table 1). Informed consent and health screen
were completed and ethical approval was granted by the
University of Hertfordshire School of Life Sciences Ethics
Committee.
Experimental design
The study was a randomised, cross-over, double-blind,
placebo controlled, 2 day repeated measure protocol.
Subjects were assigned to either the acute or chronic
intervention and the two trials ran parallel. Within each
trial subjects undertook both the magnesium interven-
tion and a placebo intervention with a one week wash-
out period in a randomised order. The two interventions
were a chronic (Chr) (4 weeks) and acute (A) (1 week)
loading strategy, sub-divided into a supplemental and a
placebo control group with a 1 week washout period. A
maximal graded exercise test for determination of VO2max
was conducted to ensure participant homogeneity with a
cut off of 45 ml/kg−1 and 35 ml/kg−1 oxygen for males
and females respectively. The study was tested across 2
consecutive days at each treatment time-point i.e. baseline
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week washout was then given and then a further interven-
tion of the opposite treatment was given (placebo or mag-
nesium) with the same loading phase.Protocol
After familiarisation, subjects were tested for baseline
measurements Anthropometric measures (height (cm),
weight (kg)) and age (y)) were recorded. All subjects
attended a familiarisation session on all equipment and
testing protocols prior to testing. On both day 1 and re-
covery day 2 participants completed a 40 km time trial
on bicycles owned by the subjects and set onto a rig. A
set 40 km flat course with no wind setting was used on a
Computrainer Pro ergometer (Computrainer, Seattle).
All on-screen course data information was blinded, verbal
encouragement was not given during the exercise testing.
The time trial was carried out to elicit physiological stress
as normally determined by training and competition. After
a 30 minute rest participants completed the following tests
to determine the effect of magnesium on strength and car-
diovascular parameters.
Blood pressure, and augmentation index (Aix) were re-
corded at rest immediately and before the bench press.
Subjects then performed a bench press corresponding to
a 5 repetition maximum (5-RM) protocol [20]) for deter-
mination of their 1-RM. Upon completion, a 5-minutes
rest period was given. Subsequently, a bench press at
80% 1-RM was performed to exhaustion. A measure of
force (Newtons) was recorded during the bench press,
with additional measures of blood pressure and Aix im-
mediately upon completion of the bench press.Table 2 Dietary intake, values are mean ± SD
Chronic Acute Chronic AcuteSupplementation
Magnesium citrate and placebo (cornflour) were capsu-
lated into large vegetarian capsules. Capsules consisted of
a total of 75 mg of elemental Mg2+ citrate, (Pioneer analyt-
ical balance. OHAUS, UK), 4 capsules per day were taken
orally, equating supplemental Mg2+ to a total daily dose of
300 mg/d elemental Mg2+. Supplements were ingested
evenly throughout the day on a non-testing day, or
ingested 3 hours before exercise testing. Finally, the sup-
plementation period for both placebo and Mg2+ accounted
for a total ingestion period of 1 week or 4 weeks within
the A and Chr groups, respectively.intervention intervention placebo
control
placebo
control
Kcal 2513 ± 1201 2686 ± 938 3985 ± 519 3785 ± 734
CHO (g) 274 ± 170 296 ± 118 397 ± 209 343 ± 79
Fat (g) 96 ± 58 115 ± 49 114 ± 63 105 ± 48
Pro (g) 119 ± 38 114 ± 37 136 ± 66 129 ± 16
Mg2+ (mg) 375 ± 104 368 ± 173 551 ± 347 378 ± 79Diet
A 4-day weighed food and beverage diary was recorded
in relation to 3 weekdays and 1 weekend day, which was
used for analysis of habitual dietary magnesium intake
through use of dietary analysis software (Dietplan 6.70
Forestfield Software, UK).Statistical analysis
Data were analysed using SPSS version 20 (IBM limited,
UK) and Microsoft excel 2007 for Windows. Box-whisker
plots measured normality/data distribution and showed
that the data were not normally distributed. Therefore
non-parametric Wilcoxon 2 related samples tests were
carried out on all results to look for differences. Alpha
value was set at 0.05.
Results
There were no statistically significant difference found
between anthropometric data, VO2max and HR deter-
mining a homogeneous cohort (Table 1).
Table 2 shows averaged dietary data for both the Chr
and A groups. Both the Chr and A control groups showed
no significant difference between macronutrient and mag-
nesium ingestion.
Performance
Bench press
Net strength gains as determined by 1-RM showed sig-
nificant increase of 17.7% with the acute Mg2+ loading
strategy compared to baseline (p = 0.031) (Figure 1). No
significant strength gains were seen in the Chr interven-
tion group (p = 0.281).
Furthermore, A Mg2+ showed no decline in recovery
(day 2) performance for force (N) resulting in a small
day 2 (recovery day) force increase of 2.7%, showing a
trend but no significnace (Figure 2). On the contrary
Chr Mg2+ showed a day-to-day 32.1% performance dec-
rement (Figure 3).
Resting SBP measures from day 1 and 2 show a sig-
nificant decrease within A Mg2+ treatment (P = 0.031),
conversely placebo showed a significant increase in
SBP (P = 0.047) (Table 3). Further, significant day 2
reductions in SBP were noted between A treatments of
Mg2+-placebo (P = 0.016). On the contrary, Chr Mg2+
shows no significant reductions in resting SBP on day 1 or
day 2.
In relation to post SBP responses, both Chr and A
Mg2+ treatment resulted in significant SBP reductions;
however, such reductions can be noted on day 1 (P =
0.016) and day 2 (P = 0.016) for a Chr Mg2+ induced SBP
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Figure 1 Acute and chronic bench press 1-RM scores on day 1 ± SD. * denotes significance.
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reduction can be accounted for on day 2 (P = 0.047) in
comparison to placebo.
Resting DBP showed no difference for day 1 to day 2 be-
tween the placebo or Mg2+.Post DBP showed no differ-
ences between Day 1 to Day 2 for acute supplementation
group (Table 4). However, chronic intervention showed
a decrease in DBP for post bench press on the recov-
ery day 2.
Although no significance was seen for Aix at rest for
both A and Chr loading strategies, a significant lowering
post bench press was found as highlighted in Table 5 on
day 1 for A treatment and day 2 for the Chr treatment
group. Day 1 Aix reductions correspond to a significant
Mg2+ lowering effect compared to baseline (P = 0.016)
and placebo (P = 0.031), respectively. Whereas, similar
Aix reductions for the Chr Mg2+ group is noted on day 20.0
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N
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Figure 2 Acute force (newtons) output on day 1 and 2 (recovery) during rpost bench press resulting in significant values of P = 0.039,
when compared to baseline and placebo, respectively.
Discussion
This study set out to determine whether either acute or
chronic magnesium supplementation would have an ef-
fect on performance (strength and cardiovascular) and
blood pressure with exercise and/or on a second bout of
exercise after a 24 hr recovery period. As has been
shown previously [13,21] acute magnesium supplemen-
tation has a positive effect on BP, plyometric parameters
and torque, however its effect on resistance exercise has
not been evident to date. Further, chronic loading strat-
egies have not been investigated in respect to exercise as
well as the effect of Mg supplementation on a second
bout of exercise. It was hypothesised that as acute Mg2+
supplementation has been seen to have beneficial effectsbo  Mg
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Figure 3 Chronic force (newtons) output on day 1 and 2 (recovery) during repetitions to fatigue ± SD.
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strategy (4 weeks) would amplify these results, giving a
more beneficial and greater response. However, this
study did not find that chronic loading of Mg2+ has a cu-
mulative effect on the effect of supplementation, perhaps
due to saturation of Mg2+ within the blood or limitations
to transporters.
Primary findings showed variance across treatment
groups on exercise (strength and recovery) and cardio-
vascular responses. The Chr Mg2+ intervention showed
no significance in performance gains for bench press net
strength and force output (Figures 1, 2 and 3). The A
Mg2+ intervention showed variance in results across all
variable analysed with some improvements being seen in
resting HR and blood pressure for both Chr and A treat-
ment groups regarding strength related performance
(Figures 1, 2, 3 and Tables 3, 4, 5).
Strength performance
Strength related performance within the bench press
showed statistical significant improvements (P = 0.031)
within the A group and Chr group. Previous research
has shown that Mg2+ significantly enhances bench press
[22] and strength performance [11,23]. Acute Mg2+ loadingTable 3 Acute and chronic group mean SBP values at rest and
2 ±SD
Physiological variable Treatment Group
C Chr A
Resting SBP (mmHg) day 1 Placebo 119 ± 7 120 ± 5*1
Mg2+ 118 ± 6 122 ± 4*2
Resting SBP (mmHg) day 2 Placebo 121 ± 8 125 ± 2*1, 3
Mg2+ 118 ± 7 117 ± 7*2, 3
*Denotes significance as paired by numbers.showed a significant net strength increase of 5.5 kg between
baseline and supplemental Mg2+ trials. Other strength re-
lated measurements of force (Newtons) illustrated A Mg2+
induced improvements. Typically, where a decrease in force
would be expected on day 2 (recovery) of training as a
normal physiological response to training, an A group
improvement of 0.25 Newtons (2.7%) was seen with
Mg2+ supplementation compared to the Chr where a 2.0
Newtons (32.1%) decrement was seen.
When examining net strength of Chr compared to A
groups a notable difference between baseline scores is
evident implying that subjects within the A group might
well be stronger due to a 7.3 kg 1-RM difference at baseline
(Figure 1). Therefore, when considering the 10.5 kg differ-
ence between Chr and A group 1-RM trials after interven-
tion of Mg2+, inter-subject lifting capacity/ability could be a
factor of concern for validating such a difference.
These performance enhancements for the strength asso-
ciated tests are suggestive of physiological-regulatory func-
tions of Mg2+ within muscle contraction and relaxation;
i.e. regulating troponin expression via Ca2+ concentration
gradients, Ca2+ transport, MgATP complex formation
optimising energy metabolism/muscular contraction, in-
creasing protein synthetic rate, protection against cellularpost bench press at 80% 1-RM to fatigue on day 1 and
Physiological variable Treatment Group
Chr A
Post SBP (mmHg) day 1 Placebo 143 ± 7*3 136 ± 5
Mg2+ 136 ± 9*3 137 ± 6
Post SBP (mmHg) day 2 Placebo 144 ± 9*4 144 ± 7*5
Mg2+ 137 ± 10*4 134 ± 5*5
Table 4 Acute and chronic group mean DBP values at rest and post bench press at 80% 1-RM to fatigue on day 1 and
2 ± SD
Physiological variable Treatment Group Physiological variable Treatment Group
Chr A Chr A
Resting DBP (mmHg) day 1 Placebo 85 ± 7 75 ± 7 Post DBP (mmHg) day 1 Placebo 92 ± 8 85 ± 12
Mg2+ 79 ± 6 75 ± 4 Mg2+ 87 ± 7 82 ± 5
Resting DBP (mmHg) day 2 Placebo 78 ± 8 79 ± 6 Post DBP (mmHg) day 2 Placebo 91 ± 5*1, 2 86 ± 13
Mg2+ 75 ± 7*1 74 ± 5*2 Mg2+ 84 ± 8*2 76 ± 8*3
*Denotes significance as paired by numbers.
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[23-26] all of which contribute to the result of increased
strength and force production. Consideration must be
given as to why such a contrasting difference between Chr
and A groups occur specifically when regarding strength
performance measures. The A Mg2+ supplemented group
showed day-to-day performance improvements across 3
trials, as opposed to 3 day-to-day non-performance im-
proved trials exhibited within the Chr Mg2+ supplemented
group which may be attributed to the different loading
strategies within the current study. The Mg2+ supplemen-
tation within the current research was 300 mg/d, therefore
equating the Chr and A group mean daily intake for
Mg2+ to 675 mg/d and 700 mg/d, respectively, when
combined with dietary Mg2+ intake as analysed from food
diaries. This adds a sense of greater ambiguity when con-
sidering the Mg2+ - strength performance relationship,
and comparing to research highlighting observations that
intakes of 500 mg/d or greater result in further increases
in strength [24,25]. It could be suggested that subjects
within the Chr loading group might be more susceptible
to a possible reduction threshold or cell tolerance for
Mg2+ absorption based upon the understanding that
high Mg2+ intakes result in a lower Mg2+ absorption
[27]. Additionally, Mg2+ homeostasis may be postulated
to exhibit no greater benefit from the chronic perspec-
tive due to the kidney function for Mg2+ excretion as
to maintain a balanced concentration of Mg2+ [27,28];
for example, could the principle of a higher Mg2+ dose,
longer supplemental duration and associated proportionalTable 5 Acute and chronic group mean Aix values post
bench press at 80% of 1-RM to fatigue on day 1 and 2 ± SD
Physiological
variable
Treatment Group
Chr A
Post Aix day 1 (%) Baseline 7 ± 11 17 ± 5*3
Placebo 9 ± 6 14 ± 6*4
Mg2+ 7 ± 5 10 ± 5*3 *4
Post Aix day 2 (%) Baseline 14 ± 7*1 12 ± 6
Placebo 14 ± 8*2 16 ± 4
Mg2+ 8 ± 12*1, 2 11 ± 6
*Denotes significance as paired by numbers.increase of Mg2+ excretion highlight the body’s effi-
ciency in maintaining a state of homeostasis? Alterna-
tively, chronic loading through providing a regular high
Mg2+ intake may influence extracellular Mg2+ concentra-
tions which coincide with manipulation of Mg2+ trans-
porter TRPM6 function, resulting in a potential decrease
in TRPM6 expression in conjunction to increasing the
urinary excretion of Mg2+ [29]. Thus, an acute ingestion
rate as opposed to chronic could result in a more efficient
use for Mg2+.
Cardiovascular responses at rest and post bench press
performance
Significant reductions in SBP and DBP are illustrated
from post testing in the chronic group and rest and post
testing in the acute group data across day 1 and 2 com-
pared to baseline and placebo (Tables 3 and 4). Resting
SBP was accounted for by a greater reduction in the A
Mg2+ of 2 mmHg, in comparison to 0.7 mmHg with the
Chr Mg2+ treatment. In addition, both resting and post
DBP showed reductions with a greater day-to-day DBP
reduction in the A Mg2+ in comparison to Chr Mg2+ as
shown by a 69.2% and 50% (9 mmHg and 3 mmHg dif-
ference) at rest and post exercise for A and Chr groups
respectively. These findings are in agreement with previ-
ous research [13,30] showing the importance of Mg2+
and its influence on blood pressure regulation. This is
supported by findings within a recent meta-analysis [19]
looking at Mg2+ supplementation which showed that
SBP and DBP reductions of 2–3 mmHg and 3–4 mmHg,
respectively. These observations oppose some previous
findings which emphasise supplemental ineffectiveness
of Mg2+ [31-33].
Such reductions in blood pressure could be speculated
as being an outcome influenced by increases within the
extracellular concentration of Mg2+, an effect that has
been associated with reductions in the arterial tension and
tone. These reductions in arterial tension and tone corres-
pond to typical Mg2+ induced vasodilatory actions which
potentiate effects of endogenous vasodilators such as ad-
enosine, K+, nitric oxide and cyclo-oxygenase-dependent
mechanisms via production of PGI2 [34]. In combination,
Mg2+ acts as an antagonist to blocking Ca2+ channels
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[37]. Thus, data within the current study concur with pre-
vious research on the efficacy of Mg2+ supplementation in
reducing blood pressure [13,38] and its capacity to sup-
press agonist vasoconstriction [4]. The above mechanisms
may also be attributed to Mg2+ induced specific alter-
ations within the vasculature, for example, Mg2+’s medi-
atory role within the endothelium corresponds to increased
nitric oxide, PGI2 and decreases platelet aggregation, in
combination to stringent down-regulation of Ca2+ voltage
operated channel activity and release from the sarcoplas-
mic reticulum [39].
Average dietary Mg2+ intakes within the A and Chr
groups corresponded to 368 mg/d and 375 mg/d, respect-
ively. However, it must be considered that the blood pres-
sure reduction in Chr and A loading strategies, may be
attributed to the Mg2+ supplementation. With this in mind,
it could be suggested that despite average dietary intakes of
Mg2+ meeting the UK RNI a higher requirement for Mg2+
may be beneficial in reducing blood pressure. Further rec-
ommendations within the U.S are 420 mg/d and 320 mg/d
for males, and females, respectively, in addition to Mg2+ re-
quirements within the UK being determined many years
ago [40]; Research by Geleijnse et al. [41] in a comparative
study between 5 European countries which included
the UK, corroborates with this study suggesting a po-
tential increase of Mg2+ based on supplemental blood pres-
sure enhancements, whereby the researchers highlighted
a <350 mg/d of Mg2+ as suboptimal, augmenting the
prevalence of hypertension. The study further accounted
for an 80% insufficiency corresponding to Mg2+ intake to
be evident within the UK population analysed [41].
A principle limitation within the current study con-
cerns lack of monitoring of the subjects’ Mg2+ status via
serum concentrations therefore this research is limited
to infer indirect associations between Mg2+ supplemen-
tation and performance from dietary intake determined
from food diaries. The study duration and the nature of
a consecutive 2 day protocol both consisting of a 40 Km
time trial can be seen as to limit the potential for subject
recruitment and therefore final number of participants re-
cruited. The use of males and females within groups must
also be noted to account for occasional group data vari-
ance, on various parameters and a high level of standard
deviation.
Conclusion
The current study showed a positive effect with A Mg2+
supplementation in relation to net strength and force
gains with bench press, findings that support previous
research [11,22,23,25]. Further, cardiovascular responses
to the bench press were significantly enhanced by Mg2+
supplementation reducing resting SBP and DBP with the
greatest effect seen with A Mg2+ supplementation for restand post exercise. Similarly, SBP, DBP and Aix showed a
significantly greater and more consistent reduction in re-
sponse to the A Mg2+ loading strategy, as opposed to the
minimalistic effect induced by Chr Mg2+ loading strategy.
In conclusion, it can be stated that improvements seen
with the A loading strategy cannot to the same extent be
observed with the Chr loading of Mg2+, thus potentially
suggesting a regulatory effect within the body influenced
by the duration of Mg2+ supplementation intake.
To conclude, from this study there appears to be no
benefit in long term magnesium supplementation for
those who have adequate dietary intake, but there are
some benefits for taking an acute dose, particularly before
intense exercise.
Future work may focus on the above parameters for
those with low dietary Mg2+ intake and also for the
optimum time that supplementation should be given to
induce these positive findings.
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